Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07584434 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, First-in-human Study of VX-433
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT07584434 is a Phase 1 study that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 118 participants.
The verdict
NCT07584434, a Phase 1 study, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Bupropion
- DRUG VX-433
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2027-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07584434
The ClinicalTrials.gov registry entry for NCT07584434 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07584434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07584434 about?
NCT07584434 is a clinical study titled "A Phase 1, First-in-human Study of VX-433". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
What is the current status of trial NCT07584434?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2026-05-21. Estimated completion is 2027-03-05.
What interventions are being tested in trial NCT07584434?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Bupropion (DRUG), VX-433 (DRUG).
Who is sponsoring clinical trial NCT07584434?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.